ACE and congenital rubella syndrome: CRS‐2. Angiotensin‐converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), sacubitril/valsartan (ARNI), mineralocorticoid antagonists, and SGLT2 inhibitors were all studied for their involvement in CRS‐2 therapy.